The Developmental Studies Hybridoma Bank (DSHB), a National Institutes of Health (NIH) national resource housed in the Department of Biology and directed by Professor David Soll, has been actively distributing hybridomas and monoclonal antibodies to companies and research institutions. These hybridomas and monoclonal antibodies are primary reagents for research directly related to the development of therapeutics for COVID-19 infections. Many are useful in developing therapeutics that function at the level of the immune response and removal of pathogens by the body, which include viruses. The DSHB is also preparing to generate monoclonal antibodies against chemically synthesized COVID-19 proteins, possible therapeutics against viral infections, using an unorthodox approach.